NASDAQ: KMTSKestra Medical Technologies Ltd Stock
$20.41-0.44 (-2.11%)
Updated Jun 15, 2026
KMTS Price
$20.41
Fair Value Price
N/A
Market Cap
$1.19B
52 Week Low
$13.25
52 Week High
$30.00
P/E
-6.15x
P/B
4.14x
P/S
16.46x
PEG
N/A
Dividend Yield
N/A
Revenue
$83.72M
Earnings
-$143.89M
Gross Margin
48.8%
Operating Margin
-162.71%
Profit Margin
-176.9%
Debt to Equity
0.32
Operating Cash Flow
-$87M
Beta
1.36
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KMTS Overview
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KMTS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
A
KMTS
Ranked#38 of 42
Ranked#38 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.80 | A | |
| $15.00 | B | |
| $21.89 | B |
Be the first to know about important KMTS news, forecast changes, insider trades & much more!
KMTS News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KMTS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KMTS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KMTS is poor value based on its book value relative to its share price (4.14x), compared to the US Medical Instruments & Supplies industry average (3.21x)
P/B vs Industry Valuation
KMTS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more KMTS due diligence checks available for Premium users.
Valuation
KMTS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.15x
Industry
42.98x
Market
14.3x
KMTS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.14x
Industry
3.21x
KMTS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KMTS's financial health
Profit margin
Revenue
$24.6M
Net Income
-$34.2M
Profit Margin
-139.2%
KMTS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
KMTS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$379.3M
Liabilities
$91.4M
Debt to equity
0.32
KMTS's short-term assets ($314.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KMTS's short-term assets ($314.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KMTS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.4M
Investing
-$14.9M
Financing
$149.2M
KMTS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KMTS vs Medical Stocks
Kestra Medical Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.